A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.

Trial Details

NCT ID
NCT06754930
Phase
PHASE1 / PHASE2
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • SHR-1826
  • SHR-1316
  • SHR-9839
  • SHR-8068
  • Ametinib mesylate
  • BP-102
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntary participation and written informed consent.
  • 18-75 years older, no gender limitation.
  • Eastern Cooperative Oncology Group (ECOG) score: 0-1.
  • With a life expectancy ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →